Targeting sphingosine-1-phosphate signalling for cardioprotection
Kennedy, S. and Kane, K.A. and Pyne, N.J. and Pyne, S. (2009) Targeting sphingosine-1-phosphate signalling for cardioprotection. Current Opinion in Pharmacology, 9 (2). pp. 194-201. ISSN 1471-4892 (https://doi.org/10.1016/j.coph.2008.11.002)
Full text not available in this repository.Request a copyAbstract
Sphingosine-1-phosphate (S1P) is a bioactive lysophospholipid generated by the sphingosine kinase (SK1 or SK2)-catalysed phosphorylation of sphingosine. Plasma S1P is carried in high-density lipoprotein (HDL) or bound to albumin and is reported to arise from activated platelets and erythrocytes. In addition, extracellular SK1 released from vascular endothelial cells may also contribute to plasma S1P levels. S1P exerts its effects through a family of five high affinity S1P-specific G protein-coupled receptors (GPCRs), S1P1-5. Various S1P receptors are present in the cardiovascular system, including cardiac tissue. Additionally, intracellular S1P may have a second messenger action. Since S1P is recognised as a survival factor in many tissues, there has been much interest in S1P as a cardioprotective agent. Recent evidence indicates that S1P can pre-condition and post-condition the heart and that the cardioprotective effect of HDL may be because of its S1P content. In addition, evidence is emerging that the cardioprotective effects of cannabinoids and S1P may be linked.
ORCID iDs
Kennedy, S., Kane, K.A., Pyne, N.J. ORCID: https://orcid.org/0000-0002-5657-4578 and Pyne, S. ORCID: https://orcid.org/0000-0002-6608-9584;-
-
Item type: Article ID code: 19202 Dates: DateEventApril 2009PublishedSubjects: Medicine > Internal medicine
Medicine > Pharmacy and materia medicaDepartment: Faculty of Science > Strathclyde Institute of Pharmacy and Biomedical Sciences Depositing user: Strathprints Administrator Date deposited: 04 Jun 2010 14:28 Last modified: 25 Oct 2024 19:03 Related URLs: URI: https://strathprints.strath.ac.uk/id/eprint/19202